SEC Form 4 · accession 0001104659-26-095111
Protagonist Therapeutics, Inc · PTGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dinesh V Ph D Patel
Officer — President and CEO · Director
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 6:43 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001377121
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2026 | M | 65,761 | $21.58 | A | 589,239 | D | |
| Common StockF2 | Aug 10, 2026 | S | 65,761 | $149.11 | D | 523,478 | D | |
| Common Stock | Aug 11, 2026 | M | 34,239 | $21.58 | A | 557,717 | D | |
| Common StockF3 | Aug 11, 2026 | S | 34,239 | $148.52 | D | 523,478 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $21.58 | Aug 10, 2026 | M | 65,761 | D | — | Oct 11, 2026 | Common Stock | 65,761 | 159,239 | D |
| Stock Option (right to buy)F1 | $21.58 | Aug 11, 2026 | M | 34,239 | D | — | Oct 11, 2026 | Common Stock | 34,239 | 125,000 | D |
Explanation of responses
- F1The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.
- F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.41 to $151.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.64 to $151.30. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.